Oxular
0 followers
‌
Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye.
Industries
Headquarters
Employees
Links
Org chart
Thomas Cavanagh
Chief Executive Officer
Thomas Cavanagh
Collapse
Ronald Yamamoto
Chief Scientific Officer
Friedrich Asmus
Chief Medical Officer
Stacey Tucker
Finance Director
John Zemba
Director, Device Training
Paul Hawkins
Director of Information Management
Paul Pritchard
Associate Director of Procurement and Supply Chain
Seán Kearney
Director, Device Training
John Perry
Finance Director
Ken Macleod
Director
Jim Jogerst
Chief Business Officer
